Several studies have found that obesity and increased adiposity mainly in the abdominal region, are associated with low-grade inflammation, insulin resistance (IR), impaired glucose homeostasis and comorbidities such as type 2 diabetes mellitus (T2D) and cardiovascular disease. The macrophage migration inhibitory factor (MIF), is a proinflammatory cytokine involved in autoimmune and inflammatory diseases. However, currently it is suggested that MIF is involved in the inflammatory process associated with obesity and the metabolic control of the complications associated with obesity. Different studies show consistently, increased serum levels of MIF in subjects with obesity, type 2 diabetes and diabetics with microvascular complications (nephropathy, retinopathy and diabetic foot syndrome). The relationship of the MIF to the regulation of glucose metabolism and apoptosis of pancreatic _ cells, and the association of some functional polymorphisms in the promoter of the MIF gene with obesity and diabetes.This review summarizes, the knowledge based on clinical and epidemiological studies on the role of MIF in obesity and type 2 diabetes. " 2014, Investigacion Clinica (Venezuela). All rights reserved.",,,,,,,,,"http://hdl.handle.net/20.500.12104/42634","http://www.scopus.com/inward/record.url?eid=2-s2.0-84908503529&partnerID=40&md5=0cd8edd1cbe7f42ec20a0a221c8eaa7
